Scott K. Thompson

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors”.

ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors

Cell Reports Medicine(2021)10.1016/j.xcrm.2021.100350

N/A

0DataRank · unranked

24 citations

Scott K. Thompson, Roger A. Smith, Mariana Da Silva Ferreira, Zahra Asgari, Andrea Knežević +7 more

Data from Development of a Small-Molecule Serum- and Glucocorticoid-Regulated Kinase-1 Antagonist and Its Evaluation as a Prostate Cancer Therapeutic

(2023)10.1158/0008-5472.c.6498402

N/A

0DataRank · unranked

0 citations

Daniel E. Frigo, Christine G. Schnackenberg, Jeffrey D. Bray, Nicholas J. Laping, Walter Trizna +7 more

Data from Development of a Small-Molecule Serum- and Glucocorticoid-Regulated Kinase-1 Antagonist and Its Evaluation as a Prostate Cancer Therapeutic

(2023)10.1158/0008-5472.c.6498402.v1

N/A

0DataRank · unranked

0 citations

Daniel E. Frigo, Christine G. Schnackenberg, Jeffrey D. Bray, Nicholas J. Laping, Walter Trizna +7 more